

5. (Amended) The method according to claim 1 wherein administration of the compound is simultaneous with administration of the nucleotide sequence.

6. (Amended) The method according to any one of claims 1-5 wherein administration of the compound and the nucleotide sequence is repeated between 1 and 4 times, at intervals of between 1 day and 18 months.

D¹
can
7. (Amended) The method according to claim 1 wherein administration of the nucleotide sequence is via the oral, nasal, pulmonary, intramuscular, subcutaneous or intradermal route.

D²
9. (Amended) The method according to claim 1 wherein administration of the compound is via the oral, nasal, pulmonary, intramuscular, subcutaneous, intradermal or topical route.

D³
11. (Amended) The method according to claim 9 wherein the compound is administered at a dose of between 0.1 mg/kg and 100 mg/kg per administration.
